COMPASS THERAPEUTICS, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
COMPASS THERAPEUTICS, INC. (CMPX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax of -$92.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2026-06-30 was -$92.00K, a 611.11% decline year-over-year.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2026-03-31 was -$439.00K.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2025-12-31 was $6.00K.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2025-09-30 was $66.00K, a 88.56% decline year-over-year.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2025 was $70.00K, a 59.54% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2024 was $173.00K, a 48.97% decline from fiscal 2023.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2023 was $339.00K.
- COMPASS THERAPEUTICS, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2022 was -$302.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$92.00K 10-Q · filed 2026-08-06 | -$531.00K 10-Q · filed 2026-08-06 | -$525.00K derived: sum of 3 quarters · filed 2026-08-06 | -$459.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$439.00K 10-Q · filed 2026-08-06 | -$433.00K derived: sum of 2 quarters · filed 2026-08-06 | -$367.00K derived: sum of 3 quarters · filed 2026-08-06 | -$349.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $72.00K derived: sum of 2 quarters · filed 2026-03-05 | $90.00K derived: sum of 3 quarters · filed 2026-08-06 | $70.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $66.00K 10-Q · filed 2025-11-05 | $84.00K derived: sum of 2 quarters · filed 2026-08-06 | $64.00K 10-Q · filed 2025-11-05 | -$212.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $18.00K 10-Q · filed 2026-08-06 | -$2.00K 10-Q · filed 2026-08-06 | -$278.00K derived: sum of 3 quarters · filed 2026-08-06 | $299.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$20.00K 10-Q · filed 2026-08-06 | -$296.00K derived: sum of 2 quarters · filed 2026-08-06 | $281.00K derived: sum of 3 quarters · filed 2026-08-06 | $280.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $301.00K derived: sum of 2 quarters · filed 2026-03-05 | $300.00K derived: sum of 3 quarters · filed 2026-03-05 | $173.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $577.00K 10-Q · filed 2025-11-05 | $576.00K derived: sum of 2 quarters · filed 2025-11-05 | $449.00K 10-Q · filed 2025-11-05 | $916.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$1.00K 10-Q · filed 2025-11-05 | -$128.00K 10-Q · filed 2025-08-11 | $339.00K derived: sum of 3 quarters · filed 2025-11-05 | $416.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-03-31 | -$127.00K 10-Q · filed 2025-11-05 | $340.00K derived: sum of 2 quarters · filed 2025-11-05 | $417.00K derived: sum of 3 quarters · filed 2025-11-05 | $56.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2023-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $544.00K derived: sum of 2 quarters · filed 2025-02-27 | $183.00K derived: sum of 3 quarters · filed 2025-02-27 | $339.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $77.00K 10-Q · filed 2024-11-12 | -$284.00K derived: sum of 2 quarters · filed 2024-11-12 | -$128.00K 10-Q · filed 2024-11-12 | $211.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$361.00K 10-Q · filed 2024-11-12 | -$205.00K 10-Q · filed 2024-08-12 | $134.00K derived: sum of 3 quarters · filed 2024-11-12 | $5.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-03-31 | $156.00K 10-Q · filed 2024-11-12 | $495.00K derived: sum of 2 quarters · filed 2024-11-12 | $366.00K derived: sum of 3 quarters · filed 2024-11-12 | -$146.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2022-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $210.00K derived: sum of 2 quarters · filed 2024-03-21 | -$302.00K derived: sum of 3 quarters · filed 2024-03-21 | -$302.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | -$129.00K 10-Q · filed 2023-11-09 | -$641.00K derived: sum of 2 quarters · filed 2023-11-09 | -$641.00K 10-Q · filed 2023-11-09 | -$641.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$512.00K 10-Q · filed 2023-11-09 | -$512.00K 10-Q · filed 2023-08-03 | -$512.00K derived: sum of 3 quarters · filed 2023-11-09 | -$512.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | $0.00 derived: sum of 3 quarters · filed 2023-05-04 | $0.00 derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-01 | $0.00 10-Q · filed 2022-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |